Mebeverine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Gastrointestinal spasm, Irritable bowel syndrome
Adult: As conventional tab: 135 mg tid. As oral susp: 150 mg tid. As modified-release cap: 200 mg bid. Dose may be gradually reduced after several weeks when the desired effect has been obtained. Treatment recommendations may vary between individual products or among countries (refer to specific product guidelines).
Child: ≥10 years As oral susp: 150 mg tid. Dose may be gradually reduced after several weeks when the desired effect has been obtained. Treatment recommendations may vary between individual products or among countries (refer to specific product guidelines).
Cách dùng
tab: Should be taken on an empty stomach. Swallow whole & do not chew due to unpleasant taste.
MR cap: May be taken with or without food. Swallow whole & do not break/chew.
Chống chỉ định
Paralytic ileus.
Thận trọng
Patient with cardiac dysrhythmia, specifically with partial or complete heart block, angina, or severe ischaemic heart disease. Renal and hepatic impairment. Children. Pregnancy and lactation.
Tác dụng không mong muốn
Gastrointestinal disorders: Indigestion, heartburn, constipation.
General disorders and administration site conditions: General malaise.
Immune system disorders: Hypersensitivity (anaphylactic reactions).
Investigations: Decreased pulse rate.
Metabolism and nutrition disorders: Anorexia.
Nervous system disorders: Dizziness, headache.
Psychiatric disorders: Insomnia.
Skin and subcutaneous tissue disorders: Urticaria, facial oedema, angioedema, exanthema.
Quá liều
Symptoms: Neurological and CV symptoms. Management: Symptomatic and supportive treatment. Gastric lavage may be considered if discovered within approx 1 hour or in case of multiple intoxications.
Tác dụng
Description:
Mechanism of Action: Mebeverine is a musculotropic antispasmodic agent with direct action on the gastrointestinal tract smooth muscle without affecting normal gut motility. The exact mechanism is unknown, but multiple mechanisms may contribute to its local effect on the gastrointestinal tract such as decrease in ion channel permeabilities, blockade of norepinephrine reuptake, local anaesthetic activity, changes in water absorption, and weak antimuscarinic and phosphodiesterase inhibitory effect.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed. Time to peak plasma concentration: Main metabolite: 1 hour (conventional tab); approx 3 hours (modified-release cap).
Distribution: Enters breast milk. Plasma protein binding: 75% to albumin.
Metabolism: Completely metabolised via hydrolysis by esterases into veratric acid and mebeverine alcohol; demethylated carboxylic acid (DMAC) is the main metabolite in plasma.
Excretion: Mainly via urine (95% as metabolites). Elimination half-life: DMAC: 2.45 hours (conventional tab); 5.77 hours (modified-release cap).
Đặc tính

Chemical Structure Image
Mebeverine

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4031, Mebeverine. https://pubchem.ncbi.nlm.nih.gov/compound/Mebeverine. Accessed Nov. 22, 2023.

Bảo quản
Store below 30°C. Storage recommendations may vary between products. Refer to specific product guidelines.
Phân loại MIMS
Thuốc chống co thắt
Phân loại ATC
A03AA04 - mebeverine ; Belongs to the class of synthetic anticholinergics, esters with tertiary amino group. Used in the treatment of functional bowel disorders.
Tài liệu tham khảo
Anon. Mebeverine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 19/07/2023.

Arrotex Pharmaceuticals (NZ) Limited. Mebeverine 135 mg Film-coated Tablet data sheet 19 April 2023. Medsafe. http://www.medsafe.govt.nz. Accessed 19/07/2023.

Aurobeverine MR 200 mg Modified-release Capsules, Hard (Milpharm Limited). MHRA. https://products.mhra.gov.uk. Accessed 19/07/2023.

Buckingham R (ed). Mebeverine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/07/2023.

Duspatalin 135 mg Coated Tablets (Abbott Laboratories [M] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 19/07/2023.

Duspatalin Retard 200 mg, Modified Release Capsules, Hard (Abbott Laboratories (S) Pte Ltd). MIMS Singapore. http://www.mims.com/singapore. Accessed 19/07/2023.

Joint Formulary Committee. Mebeverine Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/07/2023.

Mebeverine Hydrochloride 50 mg/5 mL Oral Suspension (Ardant Pharmaceuticals Ltd). MHRA. https://products.mhra.gov.uk. Accessed 19/07/2023.

Mebeverine Tablets 135 mg (Teva UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 19/07/2023.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Mebeverine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Duspatalin
  • Mebever MR
  • Verimed
  • Vermeb
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in